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Introduction
Neurodegenerative diseases are easy to diagnose but
hard to treat. Alzheimer disease (AD) is a typical exam-
ple. AD is characterized by severe memory loss, with
episodic memory being particularly impaired during the
initial phases. However, the disorder is not currently
curable [1]. The first case of AD was described by Alois
Alzheimer at the 37th meeting of the Society of
Southwest German Psychiatrists in Tubingen, Germany
[2]. A hundred years later, it is the most common neu-
rodegenerative disease in our modern but elderly society,
and this senile dementia affects more than 20 million
people worldwide [2]. The anatomy of the brain in 
AD patients shows two defining neuropathologic 
characteristics: neuritic plaques and neurofibrillary tan-
gles. Under the electron microscope, abnormal amyloid-
like filaments can be seen in the plaques and tangles
[3,4]. The localization of plaques and tangles are dif-
ferent; plaque filaments are extracellular, but most of the
tangle filaments are intracellular and are deposited in
nerve cell bodies, as well as in neurites in the neuropil.
The major molecular components of the plaques and
tangles also differ; amyloid-β (Aβ) peptide is the major
plaque component, while tau protein is the major 
tangle component. The 40–42-amino acid Aβ peptide
is derived from sequential cleavage of amyloid precur-
sor protein (APP), a type 1 transmembrane protein, 
by two proteases, β- and γ-secretase [1,2]. Transgenic
mouse models of AD targeting the APP and tau genes
have confirmed these pathogenic factors. Thus, inhibi-
tion of APP and tau expression may provide a strategy
for combating AD [1].
Because AD is not yet curable, many AD patients are
prescribed antipsychotics or antidepressants to manage
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SUMMARY
Objective: In this study, we proposed a hypothesis to explain the mechanisms of memantine action in treating
Alzheimer disease (AD). Memantine may reduce the expression of amyloid precursor protein and tau protein,
as well as acting as an antagonist of N-methyl-D-aspartate receptors in the brain.
Results: Two neuropathologic characteristics of AD are neuritic plaques and neurofibrillary tangles. The major
molecular components of the plaques and tangles are amyloid-β peptide and tau, respectively. Drugs able to
reduce the expression of amyloid-β and tau protein provide potential pharmaceutical treatments for AD. We
found that memantine inhibited internal ribosome entry site-mediated translation initiation in COS-1 cells.
This suggests that the memantine may not only inhibit neuronal excitotoxicity, but also act as an inhibitor of
the internal ribosome entry site, to block the expression of amyloid precursor protein and tau in neurons.
Conclusion: Memantine may function not only as an antagonist of N-methyl-D-aspartate receptors, but also as
an inhibitor of the internal ribosome entry site to block the expression of amyloid precursor protein and tau,
and so ameliorate the symptoms of AD. [Taiwan J Obstet Gynecol 2009;48(3):273–277]
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their neuropsychiatric and behavioral symptoms, or take
over-the-counter preparations with unknown thera-
peutic values, including Ginkgo biloba and vitamins C
and E [5–9]. Five drugs are currently approved for the
treatment of AD in the United States: (1) the cholin-
esterase inhibitors donepezil, galantamine, rivastigmine
and tacrine, and (2) the glutamate receptor antago-
nist memantine [5,10]. Tacrine, however, is now rarely
used because of its hepatotoxicity. Cholinesterase in-
hibitors can combat impairment of cholinergic neurons
in AD patients by slowing the degradation of acetyl-
choline release at synapses during neurotransmission.
Memantine prevents overstimulation of the N-methyl-
D-aspartate (NMDA) subtype of glutamate receptors
to prevent calcium-induced excitotoxicity, which may
contribute to the pathogenesis of AD and other neu-
rodegenerative conditions [11]. In clinical trials, both
cholinesterase inhibitors and memantine have shown
benefit in AD patients [5–9], but have produced only
modest effects on cognitive test scores, behavioral meas-
ures, and functional outcomes. It is interesting to note
that none of these drugs target the hallmarks of AD,
APP or tau, even though reduction of Aβ production and
tauopathies by inhibition of APP and tau expression
would be expected to ameliorate the symptoms of AD.
In this study, we proposed a hypothesis to explain
the mechanism of memantine action. Memantine may
function not only as an antagonist of NMDA receptors,
but also as an inhibitor of a novel translation initiation
mechanism, the internal ribosome entry site (IRES), so
blocking the expression of APP and tau protein and
thereby relieving the symptoms of AD.
Materials and Methods
Cell culture, plasmids, and transfection
COS-1 cells (African green monkey kidney fibroblast-like
cell line) were grown in Dulbecco’s modified Eagle’s
medium containing 10% fetal bovine serum. pGS-EV71
plasmids were generated as described by Chen et al [12].
The EV71 IRES was flanked by the β-galactosidase and
secreted alkaline phosphatase (SEAP) reporter genes.
COS-1 cells were then transfected with the plasmids
using Lipofectin reagent (Invitrogen, Carlsbad, CA, USA)
and plated onto 24-well plates at a density of 0.5–2 ×
105 cells/well. The cells were repeatedly washed with
serum-free medium to remove all traces of serum prior
to transfection. One microgram of plasmid was diluted
in 200 μL of serum-free Dulbecco’s modified Eagle’s
medium, and 1 μL of Lipofectin reagent was added.
The DNA–Lipofectin mix was incubated for 15 minutes
to allow DNA–Lipofectin complex formation, and then
transferred to the cells at a final volume of 0.5 mL in
serum-free medium. The transfected cells were then incu-
bated at 37°C in 5% CO2. After 12 hours, the transfec-
tion medium was replaced with medium containing
fetal bovine serum and antibiotics, and the cells were
cultured for a further 12 hours before being used in
the following assays.
Measurements of SEAP and b-galactosidase activity
After transfection, supernatants were harvested and
analyzed for SEAP activity using BD Great EscAPe SEAP
detection kits (Clontech Laboratories, Mountain View,
CA, USA). For the β-galactosidase activity assay, the
transfected cells were lysed for 10 minutes in 300 μL of
culture cell lysis reagent containing 100 mM potassium
phosphate (pH 7.8), 1 mM EDTA, 10% Triton X-100,
and 7 mM β-mercaptoethanol. After centrifugation at
15,200g for 30 minutes, the lysate supernatant was
assayed for β-galactosidase activity using a Luminescent
β-galactosidase Detection Kit II (BD Biosciences, San
Jose, CA, USA). The chemiluminescent intensities reflect-
ing relative SEAP activities and β-galactosidase activities
were detected using a chemical luminescence counter
(Mithras LB 940; Berthold Technologies, Bad Wildbad,
Germany). Both SEAP and β-galactosidase activities
were expressed as relative light units. The detection limit
for SEAP was about 10–13 g. Thus, the sensitivity of our
bicistronic assay was comparable with Renilla and firefly
luciferase assays. Because SEAP was secreted into the
culture medium, it was possible to measure the alkaline
phosphatase activity without lysis of the cells.
Results and Discussion
IRES and translation initiation
Translation initiation for protein synthesis in eukaryotic
cells proceeds in two ways: by a cap- and 5 end-depend-
ent mechanism and by a cap-independent mechanism
that acts through an internal RNA element called the
IRES. Most eukaryotic messenger RNAs (mRNAs) use
a cap structure (m7Gppp) at the 5 end, which is rec-
ognized by translation initiation factor eIF4F (a trimeric
complex containing the cap-binding protein eIF4E, 
a scaffold protein eIF4G and an RNA helicase eIF4A).
This cap-bound eIF4F complex interacts with the 40S
ribosome subunit bound to eIF3-eIF2-methionyl-tRNA
and then scans the 5 untranslated region of mRNA
until it detects an AUG triplet in an appropriate con-
text, allowing it to complete translation initiation [13].
By contrast, IRES-dependent translation initiation 
recruits the ribosome machinery through a stable RNA
structure, and may be cap-binding protein eIF4E 
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independent. IRES elements were first identified in the
RNAs of the Picornaviridae, which have highly struc-
tured 5 untranslated regions but no cap structure at the
5 end [14,15]. In these viruses, the IRESs can fold into
a functional secondary RNA structure and mediate
translation initiation, thereby functioning like some
protein initiation factors and allowing cap-independent
translation [16]. These results demonstrate why viruses-
encoded proteases that cleave protein translation initi-
ation factors like eIF4G can reduce the efficiency of the
host cell’s cap-dependent translation initiation and
favor virus IRES-mediated translation.
Since their first discovery in picornaviruses in 1988,
IRES elements have been shown not to be restricted 
to these small RNA viruses, but to also occur in the
genomes of retroviruses and even DNA viruses, such as
HIV and herpes simplex viruses [17]. IRES are also found
in insect viruses, like Rhopalosiphum padi virus and Perina
nuda virus [18–20]. More interestingly, IRES elements
have also been found in several cellular mRNAs [21]. In
eukaryotic cells, IRES-dependent translation of cellular
mRNAs has been reported to occur when cap-dependent
translation is impaired, for instance, under conditions
of apoptosis, heat shock stress, viral infection, and in
the G2/M phase of the cell cycle [21–23]. Further stud-
ies have also suggested that the IRES may increase
translation efficiency at postsynaptic sites following
synaptic activation [24]. This implies that IRES may play
an important function in the central nervous system.
Transcripts of APP and tau genes containing IRES
It is interesting to note that ribosomes and other com-
ponents of the translation machinery are found in neu-
rons within dendritic processes, though at lower levels
than in the cell body [25–27]. In addition, a number of
mRNAs have been shown to be transported into den-
drites and translated locally [28,29]. Moreover, many
dendritically localized mRNAs encode proteins that
are critical for certain forms of synaptic plasticity [30].
The dendritic processes may not contain all the trans-
lational machinery required to support cap-dependent
translation, and IRES may be responsible for translation
of the dendritically localized mRNAs. It has been shown
that IRES are present within the 5 leader sequences 
of five dendritically localized mRNAs: those for the
activity-regulated cytoskeletal protein, the α subunit
of calcium-calmodulin-dependent kinase II, dendrin,
microtubule-associated protein 2, and neurogranin
[24]. In addition, the translation of fibroblast growth
factor 2, which plays a fundamental role in brain func-
tions, is also regulated by IRES [31]. Recent evidence
also indicates that the hallmarks of AD, APP and tau
mRNA are translated through IRES [32,33].
Qin and Sarnow [34] found that APP mRNA asso-
ciated with polyribosomes during mitosis, when cap-
dependent translation is greatly reduced. In addition,
translation of a second cistron from a dicistronic DNA
construct increased when the APP 5 untranslated
region was placed into its intercistronic region. These
results support the fact that APP synthesis occurs
through an alternate translation initiation mechanism.
Interestingly, both elevated intracellular iron levels and
ischemia individually appear to promote AD at the level
of translation. Thus, translation initiation via IRES in the
5 leader sequences of APP and tau also provides a
potential new drug target for AD treatment.
Memantine and amantadine inhibit IRES-mediate
translation initiation
Memantine was approved as a therapeutic drug for
moderate-to-severe AD in 2002 by the European Agency
for the Evaluation of Medicinal Products, followed in
2003 by the USA Food and Drug Administration [35].
Memantine is a low-to-moderate affinity antagonist of
NMDA receptors. Despite its relatively recent approval
for AD, memantine is not a new drug. Eli Lilly synthesized
it in the early 1960s for the treatment of diabetes mel-
litus [35], and it was studied in the 1980s as a drug for
various neurologic diseases (e.g. Parkinson disease,
neurogenic bladder disorders, and coma). The first
reported use of memantine (intravenous) in patients
with AD was published in 1986 [35]. Acting as an
NMDA receptor antagonist, memantine can block the
excitotoxicity evoked by the pathogenesis of AD and
other neurodegenerative processes [1]. However, NMDA
receptors are not only involved in the excitotoxicity of
neurons but are also critical glutamate receptors that
mediate the learning and memory functions of the brain.
Thus, it is likely that memantine does not act simply as
an antagonist of NMDA receptors in AD. The structure
of memantine is similar to that of the tricyclic symmetric
amine compound, amantadine (Figure 1), which is able
to block the IRES-mediated translation of enterovirus 71
or encephalomyocarditis virus [12]. Amantadine, which
was developed in the 1960s, has diverse uses, ranging
Taiwan J Obstet Gynecol • September 2009 • Vol 48 • No 3 275
Memantine in Alzheimer Disease
NH2HCl
C CH3H
H
H
H
Memantine Amantadine Rimantadine
NH2
CH3
CH3 H
H
H
NH2HCl
Figure 1. The chemical structures of memantine, amantadine
and rimantadine.
from prevention of influenza A infection to the treatment
of Parkinson disease [36]. This result implies that
memantine, like amantadine, may act as an inhibitor of
IRES-mediated translation. Figure 2 shows that meman-
tine can block EV71 IRES activity, but does not interfere
with cap-dependent translation. This suggests that
memantine can also act as an inhibitor of the IRES,
controlling the translation of the APP and tau proteins.
We, therefore, hypothesize that memantine exerts dual
actions in the treatment of AD; it not only blocks the
excitotoxicity of NMDA receptors, but also prevents 
the expression of APP and tau proteins through IRES.
The inhibition of APP and tau expression by memantine
may be responsible for the reduction of Aβ production
and tauopathies in AD patients.
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